FISH ANALYSIS UROVYSION BILIARY TRACT MALIGNANCY
General Information
HLAB/HOL Code: FISH
UPHSM LIS Test #: 4334
Schedule: Monday - Friday
Testing Time: 2 - 5 days
Testing Lab: UP Health System-Marquette
UPHSM LIS Test #: 4334
Schedule: Monday - Friday
Testing Time: 2 - 5 days
Testing Lab: UP Health System-Marquette
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume:
Temperature:
Tube Type: See Below
Collection Info:
Sample Type: Bile duct aspirate, bile duct brushing, hepatobiliary aspirate, or hepatobiliary brushing. Preservative ThinPrep vial containing 20 mL PreservCyt or CytoLyt solution.
If performing cytology before processing specimen, aliquot half of the specimen into another ThinPrep vial. Retain 1 aliquot for cytology and submit the second aliquot for FISH analysis.
Please submit a separate ThinPrep vial for each specimen.
Limitations or Unacceptable Conditions: Submission of the residual specimen (after processing for cytology) may compromise the sensitivity of the test. A positive FISH result that does not identify the location or type of malignancy result should be correlated with concurrent cytology results.
Temperature:
Tube Type: See Below
Collection Info:
Sample Type: Bile duct aspirate, bile duct brushing, hepatobiliary aspirate, or hepatobiliary brushing. Preservative ThinPrep vial containing 20 mL PreservCyt or CytoLyt solution.
If performing cytology before processing specimen, aliquot half of the specimen into another ThinPrep vial. Retain 1 aliquot for cytology and submit the second aliquot for FISH analysis.
Please submit a separate ThinPrep vial for each specimen.
Limitations or Unacceptable Conditions: Submission of the residual specimen (after processing for cytology) may compromise the sensitivity of the test. A positive FISH result that does not identify the location or type of malignancy result should be correlated with concurrent cytology results.
Methods
Fluorescent in situ hybridization (FISH) analysis of biliary cells utilizing the UroVysion FISH probe kit (UroVysion, Abbott Molecular). Probes utilized are chromosome centromeres 3, 7, & 17 and the 9p21 locus. The hybridized cells are assessed for gains of chromosomes 3, 7 and 17.
Clinical Utilities
Detection of aneuploidy of chromosomes 3, 7 and 17 in persons suspected of having pancreatic ductal adenocarcinoma, to aid in initial diagnosis of biliary malignancy and subsequent monitoring of tumor recurrence in patients previously diagnosed with biliary malignancy.
CPT Codes
88368 x4
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Reference Range
An interpretative report will be provided.
